Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

 
• By Sten Stovall
  
T-cells
Merck KGaA says deal lets it stay invested in CAR-T field while focusing its R&D efforts • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business